Cost-effectiveness analysis of emicizumab use in hospitalized older individuals with acquired hemophilia A
Ming Y Lim, Satoko Ito, George Goshua, Nathorn Chaiyakunapruk, Minkyoung Yoo, Richard Nelson · 2026
Read Cost-effectiveness analysis of emicizumab use in hospitalized older individuals with acquired hemophilia A by Ming Y Lim, Satoko Ito, George Goshua, Nathorn Chaiyakunapruk, Minkyoung Yoo, Richard Nelson (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13571228.txt.
Description
Ming Y. Lim and co-authors model, in a 2026 cost-effectiveness analysis, adding the antibody drug emicizumab up front for hospitalized older patients with acquired hemophilia A. This is a rare autoimmune bleeding disorder where the body attacks its own clotting factor. Standard hospital care leans on bypassing agents that need frequent infusions and carry clot risks until immune treatment removes the antibody.
Despite its high price, adding emicizumab to the standard agent produced lower total direct costs and better health states in the model. Fewer bleeds and hospital days offset the drug bill. The drug remains underused in hospitals largely over cost fears. The analysis gives hospital pharmacy committees a counterintuitive case worth checking against their own prices.
Catalog record
| CREATOR | Ming Y Lim, Satoko Ito, George Goshua, Nathorn Chaiyakunapruk, Minkyoung Yoo, Richard Nelson |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |